Amgen
2Q Revenues: $3.6 billion (+14%)
2Q Earnings: $14 million (earnings were $1 billion in 2Q2005)*
YTD Revenues: $6.8 billion (+13%)
YTD Earnings: $1 billion (-46%)
Comments: Worldwide sales of Aranesp increased 26% to $1 billion and combined sales of Neulasta and Neupogen increased 12% to $1 billion in the quarter. North America sales of Enbrel increased 13% to $724 million. Sales of Epogen were down 5% to $613 million. R&D expenses increased 29% to $729 million in the quarter.
*Earnings for the quarter and YTD reflect acquired in-process R&D of $1.1 billion related to the acquisition of Abgenix.
Magazine
